EMJ Hematology 9 [Supplement 6] . 2021

Journal Info

APPROXIMATELY 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapsed/refractory forms of the disease (R/R DLBCL). With effective forms of treatment currently lacking, there is an increasing need for the development of novel therapies to successfully treat the disease. This review provides a summary of the research presented by a panel of three experts at the virtual webcast symposium conference hosted by PeerVoice on 20th May 2021.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?